PCYT2 inhibits lipid accumulation via the notch signaling pathway in chicken primary hepatocytes Authors: Huimei Wang, Zhizhong Li, Zhongjun Han, Shulu Li, Jinfang Wu, Yanli Liu, Zhouzheng Ren, Xiaojun Yang, Xin Yang Published: 2026 ABSTRACT Phosphatidylethanolamine cytidylytransferase 2 (PCYT2) is a key enzyme for phosphatidylethanolamine synthesis and plays a critical role in lipid metabolism. Our prior study revealed that PCYT2 exhibited differential expression in chicken liver between embryonic day 14 and post-hatch day 1 . However, its function and regulatory mechanism in chicken lipid metabolism remains unclear. In this study, overexpression and knockdown assays were performed to explore the role of PCYT2 in lipid metabolism using chicken primary hepatocytes, and the regulatory mechanism was further analyzed by transcriptome sequencing. The results showed that overexpression of PCYT2 significantly reduced lipid droplet content, triglyceride and total cholesterol levels in chicken primary hepatocytes. These reductions were associated with the downregulation of lipogenic-related genes and proteins (ACC and FASN) and the upregulation of fatty acid oxidation-related genes and proteins (CPT1, ACOX1, and ACSL1). Conversely, knockdown of PCYT2 produced opposite regulatory effects. Subsequently, transcriptome sequencing results demonstrated that overexpression of PCYT2 markedly suppressed the activity of the Notch signaling pathway. Activation of the Notch signaling pathway using Jagged-1 significantly attenuated the regulatory effects of PCYT2 overexpression on lipid metabolism in chicken primary hepatocytes. Specifically, Notch activation increased lipid content, upregulated the expression level of ACC and FASN, and downregulated the expression level of CPT1, ACOX1, and ACSL1 in PCYT2-overexpressing hepatocytes. In summary, these results demonstrated that PCYT2 negatively regulates lipid accumulation in chicken primary hepatocytes by enhancing fatty acid oxidation and inhibiting lipogenesis, and the Notch signaling pathway is a critical mediator of this process. This findings provide a novel molecular target to improve hepatic lipid homeostasis and reduce fat deposition in chickens. Introduction Intensive genetic selection for rapid growth and high meat production in modern poultry industry has been accompanied by undesirable excessive abdominal fat deposition and a rising prevalence of fatty liver syndrome, which compromise feed efficiency, carcass quality, and flock health (Chen et al., 2021; Yadav et al., 2024). The liver is the central organ responsible for lipid metabolism in chickens, and its physiological function is closely linked to systemic fat deposition (Jia et al., 2024). Notably, hepatic lipid metabolism undergoes dramatic reprogramming during the late chick embryonic stage, particularly from embryonic day 14 (E14) to post-hatch day 1 (D1) (Wang et al., 2024, 2025). Given that embryonic development strongly determines post-hatch performance and health (Roura et al., 2025), exploring key molecular regulators of hepatic lipid metabolism at this stage is critical for developing new approaches to alleviate fat deposition and sustain lipid homeostasis in poultry. Our prior single-nucleus transcriptome sequencing screened PCYT2 as a differentially expressed gene in chicken liver between E14 and D1 (Wang et al., 2024). Phosphatidylethanolamine cytidylyltransferase 2 (PCYT2), also known as CTP:phosphoethanolamine cytidylyltransferase, is a rate-limiting enzyme in the CDP-ethanolamine pathway responsible for phosphatidylethanolamine (PE) synthesis (Cikes et al., 2023). As a predominant membrane phospholipid, PE plays critical roles in membrane integrity, lipid trafficking, and signal transduction (Chen et al., 2025b; Gok et al., 2022; St Germain et al., 2023). Our lipidomics data further demonstrated that PE is also a differentially abundant lipid species between E14 and D1 in chicken liver (Wang et al., 2025), consistent with the expression pattern of its biosynthetic enzyme PCYT2. A large body of studies in mammals had demonstrated that the essential role of PCYT2 in lipid homeostasis. For instance, PCYT2 deficiency in mice leads to hepatic steatosis and elevated lipid content (Grapentine et al., 2022). In contrast, elevated expression of PCYT2 in mouse primary hepatocytes reduces triglyceride accumulation and suppresses lipogenic gene expression (Fullerton and Bakovic, 2010). In addition, muscle-specific deletion of PCYT2 impaired intramuscular lipid synthesis and distribution and compromised muscle and whole-body growth in mice and zebrafish (Cikes et al., 2023). Collectively, PCYT2 is a well-characterized modulator of lipid homeostasis in mammals. Nevertheless, its role in chicken hepatic lipid metabolism has not been elucidated, which prompted us to carry out the current research. In this study, we used gain- and loss-of-function approaches in chicken primary hepatocytes, together with transcriptome analysis and rescue assays, to characterize the function and regulatory mechanism of PCYT2 in hepatic lipid metabolism. Our findings establish PCYT2 as a novel regulator of poultry hepatic lipid metabolism and offer a potential target for improving lipid homeostasis in chickens. Materials and methods Animal and samples collection All animal procedures were conducted in accordance with the ethical guidelines and standards established by the Animal Care and Use Committee of Northwest A&F University (Permit Number: NWAFAC 1008). Fertilized eggs of Arbor Acres broilers were obtained from Xianyang Dacheng Poultry Co., Ltd. (Xianyang, China) and incubated under standard conditions in a commercial incubator. At E14 and D1, six embryos or chicks were randomly selected for sample collection. The liver tissues were rapidly excised, immediately frozen in liquid nitrogen, and stored at −80°C until further analysis. Isolation and culture of chicken primary hepatocytes According to a previously published method (Wang et al., 2024), the specific isolation and culture of chicken primary hepatocytes were as follows. First, the liver tissue was collected and cut into small pieces under aseptic conditions. Subsequently, the liver tissue pieces were digested at 37 °C for 60 min using PBS buffer supplemented with 0.5 g/L collagenase type Ⅳ (Sigma, St. Louis, MO, USA) and 0.6 g/L calcium chloride solution. The digested solution containing the separated cells was filtered through a 200-mesh sieve to collect the cells. Finally, the collected cells were further purified by density gradient centrifugation using chicken lymphocyte separation medium (Solarbio, Beijing, China) to obtain chicken primary hepatocytes. The purified hepatocytes were cultured in high-glucose DMEM containing 10% FBS and 1% penicillin-streptomycin at 37 °C in a 5% CO2 atmosphere, with regular replacement of the culture medium. Cell transfection and treatment The chicken primary hepatocytes were seeded in 12-well plates at a density of 4 × 105 cells per well and cultured until they reached 70% confluency. For RNA inference, PCYT2 siRNA or siNC (negative control) were transfected into the cells using a Lipofectamine® RNAiMAX (Invitrogen, MA, USA) following the manufacturer’s protocol. The siRNA sequences were as follows: siPCYT2 sense strand, 5′-GGCGAUGACAUCACCUUAATT-3′; antisense strand, 5′-UUAAGGUGAUGUCAUCGCCTT-3′; siNC sense strand, 5′-UUCUCCGAACGUGUCACGUTT-3′; antisense strand, 5′-ACGUGACACGUUCGGAGAATT-3′. For PCYT2 overexpression, the PCYT2 coding sequence was cloned into the pcDNA3.1 vector, and the pcDNA3.1-GFP null plasmid was used as the negative control. The pcDNA3.1-PCYT2 or pcDNA3.1 plasmid was transfected into the cells using Lipofectamine 2000 transfection reagent (Invitrogen, MA, USA), following the manufacturer’s instruction. To determine whether PCYT2 regulates lipid metabolism through the Notch signaling pathway. Cells were divided into three groups: NC group (transfected with empty pcDNA3.1 vector), PCYT2 group (transfected with pcDNA3.1-PCYT2 plasmid), and PJ group (transfected with pcDNA3.1-PCYT2 plasmid plus Jagged-1). In the PJ group, 24 h post-transfection with pcDNA3.1-PCYT2, the Notch pathway activator Jagged-1 was added at a final concentration of 6.25 μmol/L. All cells were harvested 48 h after transfection (24 h after Jagged-1 addition) for subsequent analyses, including RNA extraction, lipid profiling, and protein collection. Cell viability assay Cell viability was measured using the Cell Counting Kit-8 (CCK-8) assay (Biosharp, Hefei, China) according to the manufacturer’s instruction. Following transfection and the indicated treatments, chicken primary hepatocytes were incubated with 10 μL of CCK-8 solution per well for 4 h. The absorbance was then measured at 450 nm using a microplate reader. Blank wells containing culture medium without cells were used as background controls, and the absorbance values of blank wells were subtracted from those of experimental wells. Oil red O staining After discarding the complete medium, chicken primary hepatocytes were rinsed three times with PBS and fixed in 4% paraformaldehyde for 30 min. Following fixation, the cells were washed with 60% isopropanol and dried thoroughly. Next, the cells were stained with Oil Red O solution for 30 min. Then, the cells were washed three times with deionized water and observed under a microscope (Olympus, Tokyo, Japan) for image capture. For quantitative analysis, the stained Oil Red O was eluted with 100% isopropanol, and the absorbance was measured at 500 nm using a microplate reader. Triglyceride and total cholesterol assay After treatment, chicken primary hepatocytes were harvested and lysed. The triglyceride (TG) and total cholesterol (TC) contents were determined using corresponding assay kits (Nanjing Jiangcheng Bioengineering Institute, Nanjing, China) following the manufacturer’s protocols. Meanwhile, the total protein concentration of each sample was quantified using a BCA protein assay kit (Beyotime, Beijing, China). TG and TC levels were then normalized to protein concentration and expression as mmol/g protein. RNA extraction and real-time PCR Total RNA was extracted using the TRIzol reagent (AG21101, Agbio, China) and reverse-transcribed to cDNA using Evo M-MLV RT Premix (AG11706, Agbio, China) according to the manufacturer’s protocol. qPCR was performed using the SYBR green Pro Taq HS II kit (AG11741, Agibo, China) on a Roche LightCycel 96 PCR system (F. Hoffmann-La Roche AG, Basel, Swiss) following the manufacturer's instructions. Data were analyzed using the comparative 2-△△CT method, with β-actin as the housekeeping gene. Information of the primer sequences were shown in Table 1 .Table 1The primer sequences.GeneNCBI locusPrimer sequence (5′−3′)Length (bp)β-actinNM_205518.2F: AGCGAACGCCCCCAAAGTTCTR: AGCTGGGCTGTTGCCTTCACA139PCYT2NM_001291966.1F: GGCCATGGGCGATTATCTGAR: TCATCCACCCACTTGATGGC126ACCNM_205505.2F: AGTCCTGATTGAGCATGGCAR: CTCCAGATGGCGGTAGATTC172FASNNM_205155.4F: TGAAGGACCTTATCGCATTGCR: GCATGGGAAGCATTTTGTTGT96CPT1NM_001012898.1F: GAAGACGGAACACTGCAAAGGR: GGGCAAGTTGAATGAAGGCA224ACOX1NM_001006205.2F: GCCAGGTGGACTTGGAAAGAR: GCTGCCGTATAGGAACAATGAAG107ACSL1XM_046916037.1F: CGGACAGAGCAGAGTATGTGR: GCCTACGTACTGGCTGTGA74NOTCH1NM_001397796.1F: CTCCGGTTCCGTTCGGTTCR: GCTTCATCCCTCTCTGCTCC97HES1XM_040679737.2F: GGACGCGCTGAAGAAGGATAR: CAGGTGCTTGACGGTCATCT79ACACBXM_040648485.1F: GCAGTGGTTCCTCTTCCCTCR: GACCTCTCCCTTTGTCCAGC301FABP1NM_204192.4F: AGTACGAGCTCCAGTCCCATR: TGGTGTCTCCGTTGAGTTCG309ANGPTL4XM_001232283.7F: TCGTGACCACGACCTCAAAGR: TCCAGAAGATGCCCTGCTTG152 Table 1The primer sequences.GeneNCBI locusPrimer sequence (5′−3′)Length (bp)β-actinNM_205518.2F: AGCGAACGCCCCCAAAGTTCTR: AGCTGGGCTGTTGCCTTCACA139PCYT2NM_001291966.1F: GGCCATGGGCGATTATCTGAR: TCATCCACCCACTTGATGGC126ACCNM_205505.2F: AGTCCTGATTGAGCATGGCAR: CTCCAGATGGCGGTAGATTC172FASNNM_205155.4F: TGAAGGACCTTATCGCATTGCR: GCATGGGAAGCATTTTGTTGT96CPT1NM_001012898.1F: GAAGACGGAACACTGCAAAGGR: GGGCAAGTTGAATGAAGGCA224ACOX1NM_001006205.2F: GCCAGGTGGACTTGGAAAGAR: GCTGCCGTATAGGAACAATGAAG107ACSL1XM_046916037.1F: CGGACAGAGCAGAGTATGTGR: GCCTACGTACTGGCTGTGA74NOTCH1NM_001397796.1F: CTCCGGTTCCGTTCGGTTCR: GCTTCATCCCTCTCTGCTCC97HES1XM_040679737.2F: GGACGCGCTGAAGAAGGATAR: CAGGTGCTTGACGGTCATCT79ACACBXM_040648485.1F: GCAGTGGTTCCTCTTCCCTCR: GACCTCTCCCTTTGTCCAGC301FABP1NM_204192.4F: AGTACGAGCTCCAGTCCCATR: TGGTGTCTCCGTTGAGTTCG309ANGPTL4XM_001232283.7F: TCGTGACCACGACCTCAAAGR: TCCAGAAGATGCCCTGCTTG152 The primer sequences. Western blotting Total proteins were extracted using RIPA lysis buffer supplemented with PMSF at a final concentration of 1 mmol/L. Protein concentrations were measured using a BCA protein assay Kit (Beyotime, Beijing, China). Total proteins were separated by 12% SDS-PAGE and transferred onto 0.22 μm PVDF membrane. The membrane was blocked with 5% non-fat milk in TBST (Tris-buffered saline with 0.1% Tween-20) for 2 h at room temperature and then incubated with primary antibodies overnight at 4°C . After washing three times with TBST, the membrane was incubated with with HRP-conjugated secondary antibodies for 2 h at room temperature. Protein bands were visualized using an enhanced chemiluminescence (ECL) kit (Abbkine, Wuhan, China). Band intensities were quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA). Detailed information regarding antibodies used for Western blot analysis was provided in Table S1. RNA extraction, library construction, sequencing, and bioinformatics analysis Cells from the pcDNA3.1 group and pcDNA3.1-PCYT2 group were collected for the RNA-seq analysis. Total RNA was extracted using TRIzol reagent (AG21101, Agbio, China) following the manufacture’s instructions. RNA quantity and purity were measured using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, MA, USA), and RNA integrity was evaluated with an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Only samples with an RNA integrity number (RIN) ≥ 7.0 were used for library preparation. Libraries were constructed using the TruSeq Stranded Total RNA HT Sample Prep Kit (Illumina, San Diego, CA, USA) according to the manufacurer’s protocol. Paired-end sequencing was performed on an Illumina NovaSeq X Plus platform (Illumina, San Diego, CA, USA). Raw reads were filtered to remove adapters, low-quality bases, and undertermined bases. The resulting high-quality clean reads were then aligned to the reference chicken genome (Gallus gallus, GRCg6a) using HISAT2 (v2.2.1). Transcript-level expression was quantified using StringTie. Differentially expressed genes (DEGs) were identified using criteria of |log₂(fold change)| ≥ 1 and adjusted P-value < 0.05. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis and Gene Set Enrichment Analysis (GSEA) were performed using standard bioinformatics tools. Statistical analysis All experiment data were presented as the mean ± standard error of the mean (SEM). After confirming normal distribution and homogeneity of variances, data analysis was performed using unpaired two-tailed Student's t-tests for two-group comparisons, and one-way analysis of variance (ANOVA) followed by Tukey's multiple comparisons test for comparisons among three groups. A P-value < 0.05 was considered significant. Results Expression of PCYT2 in E14 and D1 Our previous single-nucleus transcriptome sequencing identified PCYT2 as a differentially expressed gene in chicken liver between E14 and D1. To validate this finding at both mRNA and protein levels, we examined PCYT2 expression in liver tissues and primary hepatocytes from E14 embryos and D1 chicks. As shown in Fig. 1, the expression of PCYT2 mRNA and the level of PCYT2 protein were significantly higher in the D1 group than in the E14 group, in both liver tissue and primary hepatocytes (P < 0.05). Collectively, these results confirmed the stage-specific expression pattern of PCYT2 in chicken liver and support the use of primary hepatocytes as a reliable model for subsequent functional studies.Fig. 1The expression of PCYT2 in the liver and hepatocytes of E14 chicken embryo and D1 chicken. (A) The mRNA expression of PCYT2 in liver tissue. (B) The mRNA expression of PCYT2 in chicken primary hepatocytes. (C) The protein level of PCYT2 in liver tissue. (D) The protein level of PCYT2 in chicken primary hepatocytes. Date are presented as the mean ± SEM. The asterisks symbol indicates significant differences *P < 0.05, **P < 0.01. The expression of PCYT2 in the liver and hepatocytes of E14 chicken embryo and D1 chicken. (A) The mRNA expression of PCYT2 in liver tissue. (B) The mRNA expression of PCYT2 in chicken primary hepatocytes. (C) The protein level of PCYT2 in liver tissue. (D) The protein level of PCYT2 in chicken primary hepatocytes. Date are presented as the mean ± SEM. The asterisks symbol indicates significant differences *P < 0.05, **P < 0.01. Effects of PCYT2 knockdown or overexpression on PCYT2 expression The mRNA expression and protein level of PCYT2 were significantly downregulated in the SiPCYT2 groups compared with the SiNC group (P < 0.05) (Figure S1A-B). Conversely, PCYT2 expression was markedly increased in the pcDNA3.1-PCYT2 group compared with the pcDNA3.1 group (P < 0.05) (Figure S1D-E). Notably, neither PCYT2 knockdown nor overexpression had a significant effect on the viability of chicken primary hepatocytes (P > 0.05) (Figure S1C and Figure S1F). Collectively, these results indicate that PCYT2 knockdown and overexpression models were successfully established without affecting cell viability, providing a reliable tool for subsequent functional studies. Effects of PCYT2 knockdown or overexpression on lipid content Oil Red O staining was performed to investigate the effect of PCYT2 on lipid accumulation in chicken primary hepatocytes. As shown in Fig. 2A–B, knockdown of PCYT2 significantly increased lipid droplet content, whereas overexpression of PCYT2 markedly decreased lipid droplet content. Consistent with these morphological observations, quantification of intracellular lipid contents revealed that TG and TC levels were significantly elevated in the siPCYT2 group compared with the siNC group (P < 0.05) (Fig. 2C). Conversely, PCYT2 overexpression significantly reduced TG and TC levels compared with the pcDNA3.1 control group (P < 0.05) (Fig. 2D). These data demonstrated that PCYT2 negatively regulates lipid accumulation in chicken primary hepatocytes.Fig. 2Effect of PCYT2 overexpression or knockdown on lipid content in chicken primary hepatocytes. (A) Oil red O staining of chicken primary hepatocytes treated with SiNC or SiPCYT2. (B) Oil red O staining of chicken primary hepatocytes treated with pcDNA3.1 or pcDNA3.1-PCYT2. (C) TG and TC content of chicken primary hepatocytes treated with SiNC or SiPCYT2. (D) TG and TC content of chicken primary hepatocytes treated with pcDNA3.1 or pcDNA3.1-PCYT2. Date are presented as the mean ± SEM. The asterisks symbol indicates significant differences *P < 0.05, **P < 0.01. Effect of PCYT2 overexpression or knockdown on lipid content in chicken primary hepatocytes. (A) Oil red O staining of chicken primary hepatocytes treated with SiNC or SiPCYT2. (B) Oil red O staining of chicken primary hepatocytes treated with pcDNA3.1 or pcDNA3.1-PCYT2. (C) TG and TC content of chicken primary hepatocytes treated with SiNC or SiPCYT2. (D) TG and TC content of chicken primary hepatocytes treated with pcDNA3.1 or pcDNA3.1-PCYT2. Date are presented as the mean ± SEM. The asterisks symbol indicates significant differences *P < 0.05, **P < 0.01. Effects of PCYT2 knockdown or overexpression on lipid metabolism related gene and protein expression The expression of lipid metabolism-related genes and proteins was analyzed to explore the role of PCYT2 in lipid metabolism in chicken primary hepatocytes. As illustrated in Fig. 3A–B, compared with the SiNC group, the SiPCYT2 group exhibited significantly increased mRNA expression of lipogenic genes, including acetyl-CoA carboxylase (ACC) and fatty acid synthase (FASN) (P < 0.05). In contrast, the mRNA expression of fatty acid oxidation-related genes, including carnitine palmitoyltransferase 1 (CPT1), acyl-CoA oxidase 1 (ACOX1), and acyl-CoA synthetase long chain family member 1 (ACSL1), were markedly decreased in the siPCYT2 group (P < 0.05). Consistently, the protein levels of ACC, FASN, CPT1, ACOX1, and ACSL1 exhibited similar changes (P < 0.05). Additionally, overexpression of PCYT2 significantly downregulated both gene and protein expression of ACC and FASN, while upregulating those of CPT1, ACOX1, and ACSL1 (P < 0.05) (Fig. 3C–D) . These data indicated that PCYT2 plays a crucial regulatory role in lipid metabolism of chicken primary hepatocytes by modulating the expression of key lipogenic and fatty acid oxidative-related genes and their corresponding proteins, specifically inhibiting lipogenesis and promoting fatty acid oxidation.Fig. 3Effect of PCYT2 overexpression or knockdown on lipid metabolism in chicken primary hepatocytes. (A) The expression levels of gene related to lipid metabolism after interference PCYT2. (B) The expression levels of protein related to lipid metabolism after interference PCYT2. (C) The expression levels of gene related to lipid metabolism after overexpressing PCYT2. (D) The expression levels of protein related to lipid metabolism after overexpressing PCYT2. Date are presented as the mean ± SEM. The asterisks symbol indicates significant differences *P < 0.05, **P < 0.01. Effect of PCYT2 overexpression or knockdown on lipid metabolism in chicken primary hepatocytes. (A) The expression levels of gene related to lipid metabolism after interference PCYT2. (B) The expression levels of protein related to lipid metabolism after interference PCYT2. (C) The expression levels of gene related to lipid metabolism after overexpressing PCYT2. (D) The expression levels of protein related to lipid metabolism after overexpressing PCYT2. Date are presented as the mean ± SEM. The asterisks symbol indicates significant differences *P < 0.05, **P < 0.01. Transcriptomic sequencing analysis of the hepatocytes with overexpression of PCYT2 To further investigate the mechanisms by which PCYT2 regulates lipid metabolism in chicken primary hepatocytes, transcriptome sequencing was conducted on cells from the pcDNA3.1 group and the pcDNA3.1-PCYT2 group. As shown in Fig. 4A–B and Table S2, a total of 459 DEGs were identified between the two groups, of which 82 genes were upregulated and 377 genes were downregulated in the pcDNA3.1-PCYT2 group. Among these DEGs, we also identified the lipid metabolism-related genes ACC, FASN, CPT1, ACOX1, and ACSL1 that we had previously validated by qPCR and Western blot (Table S2 and Fig. 3C–D). KEGG enrichment analysis revealed that the DEGs were primarily enriched in several pathways, including the Notch signaling pathway, MAPK signaling pathway, FOXO signaling pathway, PPAR signaling pathway, and fatty acid biosynthesis (P < 0.05) (Fig. 4C). Furthermore, GSEA confirmed significant enrichment of the Notch signaling pathway, which was remarkably downregulated in the pcDNA3.1-PCYT2 group (P < 0.05) (Fig. 4D–E). Based on the above results, we speculated that PCYT2 regulated lipid metabolism by inhibiting the Notch signaling pathway.Fig. 4Transcriptome analysis of chicken primary hepatocytes treated with pcDNA3.1 or pcDNA3.1-PCYT2. (A) The volcano plot of DEGs in chicken primary hepatocytes. (B) DEGs number statistics. (C) KEGG enrichment analysis of DEGs in chicken primary hepatocytes. (D) GESA of transcriptome. (E) GSEA of Notch signaling pathway. Transcriptome analysis of chicken primary hepatocytes treated with pcDNA3.1 or pcDNA3.1-PCYT2. (A) The volcano plot of DEGs in chicken primary hepatocytes. (B) DEGs number statistics. (C) KEGG enrichment analysis of DEGs in chicken primary hepatocytes. (D) GESA of transcriptome. (E) GSEA of Notch signaling pathway. To validate the accuracy of the RNA-seq data, six DEGs were randomly selected for qPCR verification. Consistent with the RNA-seq data, the expression levels of PCYT2 and fatty acid binding protein 1 (FABP1) were significantly increased in the pcDNA3.1-PCYT2 group, while the expression levels of Notch receptor 1 (NOTCH1), hes family bHLH transcription factor 1 (HES1), acetyl-CoA carboxylase beta (ACACB), and angiopoietin-like 4 (ANGPTL4) were significantly decreased (Fig. 5A). In addition, we further verified the expression of key components of the Notch signaling pathway at the protein level using Western blot analysis. As shown in Fig. 5B, compared with the pcDNA3.1 group, the protein levels of NICD, Notch1, and Hes1 were significantly downregulated in the pcDNA3.1-PCYT2 group (P < 0.05). Conversely, PCYT2 knockdown led to significantly increased expression of these key proteins (P < 0.05) (Fig. 5C). Therefore, these results confirm the accuracy and reliability of the RNA-seq data and further support the conclusion that PCYT2 suppresses the Notch signaling pathway in chicken primary hepatocytes.Fig. 5Validation of transcriptome analysis result. (A) Validation of DEGs by qPCR. (B) The expression level of protein (NICD, Notch1, and Hes1) in chicken primary hepatocytes after overexpressing PCYT2. (C) The expression level of protein (NICD, Notch1, and Hes1) in chicken primary hepatocytes after interference PCYT2. Date are presented as the mean ± SEM. The asterisks symbol indicates significant differences *P < 0.05, **P < 0.01. Validation of transcriptome analysis result. (A) Validation of DEGs by qPCR. (B) The expression level of protein (NICD, Notch1, and Hes1) in chicken primary hepatocytes after overexpressing PCYT2. (C) The expression level of protein (NICD, Notch1, and Hes1) in chicken primary hepatocytes after interference PCYT2. Date are presented as the mean ± SEM. The asterisks symbol indicates significant differences *P < 0.05, **P < 0.01. PCYT2 regulates lipid metabolism in hepatocytes by inhibiting notch signaling pathway To further validate the hypothesis that PCYT2 regulates lipid metabolism by inhibiting the Notch signaling pathway in chicken primary hepatocytes, hepatocytes overexpression PCYT2 were treated with Jagged-1, a well-established activator of the Notch signaling pathway. Firstly, we examined the effect of Jagged-1 treatment on Notch signaling pathway activation. As shown in Fig. 6A, Jagged-1 treatment significantly upregulated the mRNA expression level of the downstream target gene HES1 compared with the NC group (P < 0.05), confirming that Jagged-1 effectively activates the Notch signaling pathway in chicken primary hepatocytes. Subsequently, Western blot analysis showed that the protein levels of NICD, Notch1, and Hes1 were significantly higher in the Jagged-1 group than in the NC group (P < 0.05) (Fig. 6B), further supporting the activation of the Notch signaling pathway by Jagged-1.Fig. 6The effect of Jagged-1 treatment on expression of Notch signaling pathway in chicken primary hepatocytes. (A) The mRNA expression of Hes1 gene in chicken primary hepatocytes. (B)The protein expression of NICD, Notch1, and Hes1 in chicken primary hepatocytes. Date are presented as the mean ± SEM. The asterisks symbol indicates significant differences *P < 0.05, **P < 0.01. The effect of Jagged-1 treatment on expression of Notch signaling pathway in chicken primary hepatocytes. (A) The mRNA expression of Hes1 gene in chicken primary hepatocytes. (B)The protein expression of NICD, Notch1, and Hes1 in chicken primary hepatocytes. Date are presented as the mean ± SEM. The asterisks symbol indicates significant differences *P < 0.05, **P < 0.01. We next investigated whether Notch activation could reverse the effects of PCYT2 overexpression on lipid metabolism. As shown in Fig. 7A–B, co-treatment with Jagged-1 significantly reversed the reduction in lipid droplet accumulation, as well as TG and TC content in hepatocytes, induced by PCYT2 overexpression (P < 0.05). Subsequently, the mRNA expression levels of lipid metabolism-related genes were assessed (Fig. 7C). Compared with the PCYT2 group, the PJ group exhibited significantly increased mRNA expression levels of ACC, FASN, and ANGPTL4, while the mRNA levels of CPT1, ACOX1, and ACSL1 were markedly decreased (P < 0.05). In parallel, Western blot analysis demonstrated that Jagged-1 intervention significantly abrogated the PCYT2 overexpression-induced the decrease in the protein abundance of ACC and FASN, as well as the increase in the protein abundance of CPT1, ACOX1, and ACSL1 (P < 0.05) (Fig. 7D). Therefore, activation of the Notch signaling pathway weakens the regulatory effect of PCYT2 overexpression on lipid metabolism in hepatocytes, suggesting that PCYT2 modulates lipid metabolism in chicken primary hepatocytes, at least in part, by suppressing the Notch signaling pathway.Fig. 7PCYT2 regulates lipid metabolism in chicken primary hepatocytes via inhibiting Notch signaling pathway. (A) Oil red O staining. (B) TG and TC content. (C) The expression levels of gene related to lipid metabolism. (D) The expression levels of protein related to lipid metabolism. Date are presented as the mean ± SEM. The asterisks symbol indicates significant differences *P < 0.05, **P < 0.01. PCYT2 regulates lipid metabolism in chicken primary hepatocytes via inhibiting Notch signaling pathway. (A) Oil red O staining. (B) TG and TC content. (C) The expression levels of gene related to lipid metabolism. (D) The expression levels of protein related to lipid metabolism. Date are presented as the mean ± SEM. The asterisks symbol indicates significant differences *P < 0.05, **P < 0.01. Discussion In chickens, liver is the central organ responsible for lipid metabolism. In particular, significant changes in lipid metabolism have been observed during the late stage of chick embryonic development (Wang et al., 2024, 2025). This process is finely regulated by a variety of factors, including diet, environmental conditions, genetics, functional genes, and transcription factors (Chen et al., 2024; Xu et al., 2023; Zhu et al., 2023). Accumulating evidence has demonstrated that a wide range of genes play critical roles in the regulation of lipid metabolism by encoding transcription factors, metabolic enzymes, and signaling molecules (Cao et al., 2026; Xu et al., 2026). PCYT2 serves as a key node in the CDP-ethanolamine pathway, where it catalyzes the rate-limiting step of PE production, thereby playing an important role in PE synthesis and lipid homeostasis (Cikes et al., 2023; Pu et al., 2026). Notably, our earlier work identified PCYT2 as a differentially expressed gene in E14 and D1 using single-nucleus transcriptome sequencing (Wang et al., 2024). In the present, we validated this gene in E14 and D1 liver tissues and primary hepatocytes at the mRNA and protein levels, obtaining results consistent with the transcriptomic data. During the late chick embryonic development (E14 to D1), hepatic lipid metabolism undergoes extensive reprogramming, including changes in lipogenesis, fatty acid oxidation, and lipoprotein secretion (Moran, 2007). The dynamic expression pattern of PCYT2 at E14 and at D1 coincides with this metabolic remodeling, speculating that PCYT2 may be involved in regulating lipid metabolism during the late stage of chicken embryonic development. Although many studies have investigated the role of PCYT2 in regulating lipid metabolism in humans and mice, its regulatory function and potential mechanisms in poultry have not yet been explored. Hepatic lipid metabolism is primarily modulated by the balance between fatty acid synthesis and oxidation (Miao et al., 2025). To deeply explore the biological functions of PCYT2 in hepatic lipid metabolism of chickens, we employed a gain- and loss-of-function approaches in primary hepatocytes. Our results showed that PCYT2 overexpression significantly reduced lipid droplet deposition, TG and TC content, accompanied by upregulation of fatty acid oxidation-related genes (CPT1, ACOX1, and ACSL1) and downregulation of lipogenesis related factors (ACC and FASN) at both mRNA and protein level. These findings are consistent with observations in mouse primary hepatocytes overexpressing PCYT2, which also exhibited reduced hepatocytes lipid synthesis and TG content (Fullerton and Bakovia, 2010). Conversely, silencing of PCYT2 expression significantly increased lipid content in chicken primary hepatocytes. The result agrees with studies in PCYT2-deficient mice, which showed elevated lipid content in the liver (Grapentine et al., 2022). Together, these findings provided direct evidence that PCYT2 plays an essential role in regulating hepatic lipid metabolism in chickens. Furthermore, they suggest that targeting PCYT2 expression could affect lipid mobilization and deposition in chicken embryos or broilers, thereby potentially influencing their growth and development. To further elucidate the molecular mechanisms by which PCYT2 regulates lipid metabolism in chicken primary hepatocytes, we performed transcriptome analysis on PCYT2-overexpression hepatocytes. Transcriptome sequencing revealed DEGs involved in lipid metabolism, with significant enrichment in pathways such as PPAR signaling pathway and fatty acid biosynthesis. Among these DEGS, ACACB and ANGPTL4 were prominently downregulated, while FABP1 was significantly upregulated in PCYT2-overexpression hepatocytes. The main role of ACACB is to produce malonyl CoA, which is an effective inhibitor of CPT1 and further effectively inhibits the oxidation of fatty acids (Hong et al., 2022). ANGPTL4 primarily inhibits lipoprotein lipase activity, thereby modulating triglyceride metabolism and lipid accumulation (Li et al., 2024). FABP1, a fatty acid binding proteins, participates in fatty acid uptake, transport, fatty acid esterification, and the synthesis of phospholipids (Chen et al., 2025a; Wu et al., 2025). The downregulation of ACACB and ANGPTL4, together with the upregulation of FABP1, is fully consistent with the lipid-lowering phenotype observed following PCYT2 overexpression. These findings further support the role of PCYT2 in regulating lipid metabolism in chicken primary hepatocytes. In addition to the lipid‑related changes described above, our transcriptome analysis revealed that PCYT2 overexpression significantly suppressed the Notch signaling pathway, as demonstrated by both KEGG enrichment analysis and GSEA. Among all significantly enriched pathways, Notch signaling pathway exhibited the lowest P-value in the KEGG enrichment analysis. GSEA further confirmed a robust negative enrichment of this pathway. Moreover, compared with the well-characterized MAPK, FOXO, and PPAR signaling pathway, which have been shown to participate in PCYT2-meditaed lipid metabolism (Grapentine et al., 2023; Taylor et al., 2016), the role of Notch signaling pathway in this context remains largely unexplored. The Notch signaling pathway is an evolutionarily highly conserved intercellular signaling mechanism that regulates tissue development, homeostasis, and cell fate determination (Zhou et al., 2022). Recent studies have demonstrated its role in regulating lipid metabolism (Ding et al., 2023; Souilhol et al., 2022). Specifically, inhibition of the Notch signaling pathway has been showed to reduce the expression of key enzymes involved in de novo lipogenesis (ACC and FASN) and decrease hepatic TG concentrations (Pajvani et al., 2013). In addition, Notch1 inhibition enhanced hepatic fatty acid oxidation ability by increasing the expression of fatty acid oxidation-related genes, including CPT1, ACOX1 and PPARα (Madduma Hewage et al., 2022). Based on these convergent lines of evidence, we hypothesized that PCYT2 regulated lipid metabolism in chicken primary hepatocytes by inhibiting the Notch signaling pathway. To test this hypothesis, we performed rescue experiments using Jagged-1, a well-established Notch ligand that activates Notch1 (Li et al., 2022). As expected, Jagged‑1 treatment successfully activated the Notch signaling pathway, as evidenced by increased protein levels of NICD, Notch1, and Hes1. Notably, activation of the Notch signaling pathway significantly attenuated the regulatory effects of PCYT2 overexpression on lipid metabolism. Compared with the PCYT2 group, the PJ group exhibited significantly increased lipid droplet content, TG and TC levels, as well as evaluated expression of lipid synthesis‑related genes and proteins (ACC and FASN). In contrast, the expression levels of fatty acid oxidation‑related genes and proteins (CPT1, ACOX1, and ACSL1) were markedly decreased in the PJ group. These findings indicated that activation of the Notch signaling pathway interferes with the lipid-lowering effects of PCYT2 overexpression in chicken primary hepatocytes. Collectively, these results supported the hypothesis that PCYT2 exerts its regulatory effects on hepatic lipid metabolism, at least in part, through suppression of the Notch signaling pathway. This study is the first to establish a functional link between PCYT2 and lipid metabolism in poultry, and to identify the PCYT2-Notch axis as a novel regulatory mechanism in hepatocyte lipid homeostasis. These findings provided a molecular rationale for the stage-specific expression of PCYT2 during the late chick embryonic development. From an applied perspective, PCYT2 could represent a potential target for modulating hepatic lipid metabolism in broilers or laying hens, with possible implications for preventing fatty liver hemorrhagic syndrome. Conclusion In conclusion, our results reveal that PCYT2 modulates lipid metabolism in chicken primary hepatocytes by enhancing fatty acid oxidation and inhibiting lipogenesis. This action facilitates lipid mobilization and reduces hepatic lipid deposition in chick embryos. Mechanistically, we verify that the lipid-regulating function of PCYT2 is mediated, at least partially, by inhibiting the Notch signaling pathway. Notably, this study is the first to establish a functional link between PCYT2 and the Notch pathway in the regulation of hepatic lipid metabolism in poultry. Our findings also suggest that PCYT2 could serve as a promising molecular target to maintain lipid homeostasis in chickens. Author contributions Huimei Wang conceived the study, conducted the cell experiments and sample measurements, analyzed the data, interpreted the results, and drafted the manuscript. Zhizhong Li participated in study design, data analysis and interpretation, and revised the manuscript. Zhongjun Han, Shulu Li, and Jinfang Wu participated in experimental measurements, contributed to data analysis, and revised the manuscript. Yanli Liu, Zhouzheng Ren, and Xiaojun Yang contributed to the conception and critically revised the manuscript for important intellectual content. Xin Yang contributed to the conception and design of the study, data interpretation, and critical development of the scientific content of the manuscript, and supervised the overall research. All authors read and approved the final version of the manuscript and agree to be accountable for the integrity of the work. Ethics declaration This study was conducted in accordance with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines. This study was approved by the Animal Care and Use Committee of Northwest A&F University . Disclosures The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.